UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2018
Dova Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
|
001-38135 |
|
81-3858961 |
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
240 Leigh Farm Road, Suite 245 |
|
27707 |
Registrants telephone number, including area code: (919) 748-5975
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 1.02. Termination of a Material Definitive Agreement.
On March 30, 2018, AkaRx, Inc. (AkaRx), a wholly-owned subsidiary of Dova Pharmaceuticals, Inc. (the Company), and PBM Capital Group, LLC (PBM) agreed to terminate the Services Agreement, by and between AkaRx and PBM, dated April 1, 2016 (the Services Agreement), effective as of March 31, 2018. Under the Services Agreement, PBM has provided certain scientific and technical, accounting, operations and back office support services to AkaRx. PBM is controlled by Paul B. Manning, one of the Companys directors and a beneficial owner of more than 5% of the Companys common stock.